EXPIRED
Participating Organization(s) |
National Institutes of Health (NIH) |
National Cancer Institute (NCI) |
|
Funding Opportunity Title |
Limited Competition: Restoration of New Investigator Pilot Projects Adversely Affected by Hurricane Sandy (R21) |
Activity Code |
R21 Exploratory/Developmental Research Grant Award |
Announcement Type |
New |
Related Notices |
|
Funding Opportunity Announcement (FOA) Number |
RFA-OD-13-005 |
Companion Funding Opportunity |
RFA-OD-13-006, S10 Biomedical Research Support Shared Instrumentation |
Catalog of Federal Domestic Assistance (CFDA) Number(s) |
93.095 |
Funding Opportunity Purpose |
This Funding Opportunity Announcement (FOA) solicits applications from research institutions damaged as a result of Hurricane Sandy for the purpose of supporting recovery and restoration of new and early stage investigator pilot research and data destroyed or damaged as a result of the hurricane. Benefits of this award are restricted to the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia. |
Posted Date |
April 15, 2013 |
Open Date (Earliest Submission Date) |
May 19, 2013 |
Letter of Intent Due Date(s) |
May 19, 2013 |
Application Due Date(s) |
June 19, 2013, by 5:00 PM local time of applicant organization. |
AIDS Application Due Date(s) |
Not Applicable |
Scientific Merit Review |
August 2013 |
Advisory Council Review |
October 2013 |
Earliest Start Date |
November 1, 2013 |
Expiration Date |
June 20, 2013 |
Due Dates for E.O. 12372 |
Not Applicable |
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
In October 2012, Hurricane Sandy devastated parts of the Northeast United States. The storm affected numerous communities, including the biomedical communities located in this region. NIH is issuing several funding opportunities specifically to help restore and re-build the research and research infrastructure in the biomedical research institutions damaged as a result of Hurricane Sandy. Benefits of this award are restricted to the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia. This funding opportunity will be funded through funds received under the Disaster Relief Appropriations Act of 2013 (P.L. 113-2).
In keeping with NIH’s longstanding support of new and early stage investigators, this Funding Opportunity Announcement (FOA) solicits applications from research institutions damaged as a result of Hurricane Sandy for the purpose of supporting the recovery and restoration of pilot research and data destroyed or damaged as a result of the hurricane by new and early stage investigators. Restoration of these data will assist new and early stage investigators to rebuild the data and infrastructure needed to again be poised to launch competitive independent research careers. NIH expects that recipients of awards from this FOA will be able to redevelop the pilot data needed to submit an NIH research project grant application within one or two years.
Using the NIH Exploratory/Development Grant (R21) funding mechanism, this FOA focuses on new and early stage investigators with projects in early and conceptual stages (i.e. pilot projects), that could provide a basis for more extended research.
This is a one-time funding opportunity. Applicants must describe how they will accommodate the resources they are requesting in the event that major renovations or re-establishment of resources is required in order to perform the proposed research. Applications also should describe efforts undertaken since the hurricane to recover and restore research and data.
Principal investigators must be new or early stage investigators as defined by NIH (see NIH New and Early Stage Investigator Policies).
Funds provided by the NIH through this FOA cannot duplicate nor overlap with reimbursement provided by FEMA, under a contract for insurance, or by self-insurance.
Funds will be provided in a single award with a 24-month budget and project period. No-cost extensions will not be available. Therefore the applicant must assure that the scope of work proposed and outlays of awarded funds can be completed within this 24-month period.
Applications must meet the following criteria to be considered responsive:
Applications meeting any of the following criteria will be considered non-responsive and will be not proceed to peer review:
Funding Instrument |
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. |
Application Types Allowed |
New |
Funds Available and Anticipated Number of Awards |
The number of awards is contingent upon funds received by NIH from the Disaster Relief Appropriations Act and the submission of a sufficient number of meritorious applications. The NIH intends to commit up to approximately $2 million; awards will be made in FY2014. The extent and severity of damages on the research and directly related to Hurricane Sandy will be used in prioritizing funding decisions. |
Award Budget |
The combined budget for direct costs for the two year budget and project period may not exceed $100,000. No more than $50,000 direct costs may be requested in any single year. Applicable F&A costs should also be requested. Award funds shall be expended within 24 months of the Initial Issue Date listed on the Notice of Award. |
Award Project Period |
The total project period may not exceed 2 years. Funds will be provided in a single award with a 24-month budget and project period. No-cost extensions will not be available. Therefore the applicant must assure that the scope of work proposed and outlays of awarded funds can be completed within this 24-month period. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Eligibility is limited to research institutions located in the FEMA declared major disaster states, which are: Connecticut, Delaware, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Virginia, West Virginia, and the District of Columbia.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant organizations must complete the following registrations as described in the SF424 (R&R) Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.
All Program Directors/Principal Investigators (PD(s)/PI(s))
must also work with their institutional officials to register with the eRA
Commons or ensure their existing eRA Commons account is affiliated with the eRA
Commons account of the applicant organization.
All registrations must be completed by the application due date. Applicant
organizations are strongly encouraged to start the registration process at
least 6 weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
Individuals proposed as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) must be new or early stage investigators as defined by NIH New and Early Stage Investigator Policies.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Weihua Luo, PhD
Center for Scientific Review (CSR)
National Institutes of Health
6701 Rockledge Drive
Room 5114, MSC 7808
Bethesda, MD 20892 (20817-FedEx)
Telephone: 301-435-1170
Fax: 301-480-2241
Email: [email protected]
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for submission of applications for this FOA. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate optional components.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Facilities and Other Resources: Provide a letter from the institution that verifies that pilot research data existed prior to the hurricane and that describes the extent of the damage, destruction or loss resulting from the hurricane, including staff time, research materials, resources, supplies, and preliminary data. The letter must confirm that the application does not request any funding that overlaps with FEMA, under a contract for insurance, or self insurance payments. The letter must be signed by an institutional Signing Official.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Due to the special monitoring and reporting requirements of the Disaster Relief Appropriations Act, the application must include a detailed R&R budget for all budget periods. Applications that include Modular Budgets will not be accepted. Applicants should disregard any submission warnings regarding the use of modular budgets in these applications.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Research Strategy: Include a description of damages and loss that occurred as a result of Hurricane Sandy. The Research Strategy should describe the research planned and the type of data expected to be regenerated. The Research Strategy should also describe how the applicant will accommodate the resources in the event that major renovations or re-establishment of resources are required in order to perform the proposed research. A clear timeline for execution and completion must be included.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.
Applicants are responsible for viewing their application before the deadline in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Funds will be awarded in a single action using a 24-month budget and project period. Awarded funds shall be expended within 24-months of the Initial Issue Date listed on the Notice of Award. No-cost extensions will not be available.
Awards will be subject to quarterly financial and programmatic reporting requirements. Details for submitting these required reports will be provided in the Terms of Award.
Funds will be restricted so that they cannot duplicate costs reimbursed by FEMA, under a contract for insurance or self insurance. If during the period of the award a claim is paid which provides such duplication, the grantee will be required to pay back the funds to the NIH.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the
Credential field of the Senior/Key Person Profile Component of the
SF424(R&R) Application Package. Failure to register in the Commons
and to include a valid PD/PI Commons ID in the credential field will prevent
the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the eRA
Commons and for theSystem for Award Management (SAM). Additional information
may be found in the SF424 (R&R) Application Guide.
See more
tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review and responsiveness by NIH programmatic staff. Applications that are incomplete and/or nonresponsive will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
For this FOA, extensive background material or preliminary information is not expected due to the loss of this preliminary data as a result of Hurricane Sandy. Accordingly, reviewers will focus their evaluation on the conceptual framework and the potential to significantly advance our knowledge or understanding of the research field. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of
human subjects from research risks, and 2) inclusion of minorities and members
of both sexes/genders, as well as the inclusion of children, justified in terms
of the scientific goals and research strategy proposed?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to subjects,
2) adequacy of protection against risks, 3) potential benefits to the subjects
and others, 4) importance of the knowledge to be gained, and 5) data and safety
monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Human
Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
Not Applicable
Renewals
Not Applicable
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Not Applicable.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the CSR, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH
Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, SAM
Registration, and Transparency Act requirements as noted on the Award
Conditions and Information for NIH Grants website. Awards will be subject
to additional quarterly financial and programmatic reporting requirements.
Details for submission of these required reports will be provided in the terms
of award.
Funds will be awarded using a single 24-month budget and project period. Awarded funds shall be expended within 24-months of the Initial Issue Date listed on the Notice of Award. No-cost extensions will not be available. All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. With the exceptions noted above, for these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Awards will be subject to additional quarterly financial and programmatic reporting requirements. The NIH will closely monitor all grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
Quarterly financial and programmatic reporting is required of all grantees. Awards may be subject to additional reporting requirements as determined by HHS.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
Grants.gov
Customer Support (Questions regarding Grants.gov registration and
submission, downloading or navigating forms)
Contact Center Phone: 800-518-4726
Email: [email protected]
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: [email protected]
eRA Commons Help Desk (Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: [email protected]
Bernard Talbot, M.D. PhD
National Center for Advancing Translational Sciences (NCATS)
Phone: 301-435-0793
Email: [email protected]
John Williamson, PhD
National Center for Complementary and Alternative Medicine
(NCCAM)
Phone: 301-496-2583
Email: [email protected]
Stephen T. White, PhD
National Cancer Institute (NCI)
Phone: 240-276-6180
Email: [email protected]
Lisa A. Neuhold, PhD
National Eye Institute (NEI)
Phone: 301-451-2020
Email: [email protected]
Bettie J. Graham, PhD
National Human Genome Research Institute (NHGRI)
Phone: 301-435-7858
Email: [email protected]
Robert Musson, PhD
National Heart, Lung and Blood Institute (NHLBI)
Phone: 301-435-0261
Email: [email protected]
James Griffin, PhD
Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD)
Phone: 301/435-2307
Email: [email protected]
David Shurtleff, PhD
National Institute on Drug Abuse (NIDA)
Phone: 301-443-6480
Email: [email protected]
Darren Sledjeski, PhD
National Institute of General Medical Sciences (NIGMS)
Phone: 301-594-0943
Email: [email protected]
Robin A. Barr, DPhil
National Institute on Aging (NIA)
Phone: 301-496-9322
Email: [email protected]
Abraham P. Bautista, PhD
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phone 301-443-9737
Email: [email protected]
Patricia Haggerty, PhD
National Institute of Allergy and Infectious Diseases
(NIAID)
Phone: 301-451-2615
Email: [email protected]
Laura K. Moen, PhD
National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS)
Phone: 301-451-6515
Email: [email protected]
Christina H Liu, PhD, PE
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Phone: 301-451-7638
Email: [email protected]
Judith A. Cooper, PhD
National Institute on Deafness and Other Communication
Disorders (NIDCD)
Phone: 301-496-5061
Email: [email protected]
Lillian Shum, PhD
National Institute of Dental and Craniofacial Research
(NIDCR)
Phone: 301-594-0618
Email: [email protected]
Teresa L. Z. Jones, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phone: 301 435-2996
Email: [email protected]
Cindy Lawler, PhD
National Institute of Environmental Health Sciences (NIEHS)
Phone: 919-316-4671
Email: [email protected]
Rebecca Claycamp, MS
National Institute of Mental Health (NIMH)
Phone: 301-443-2811
Email: [email protected]
Nathan Stinson, Jr., MD, PhD, MPH
National Institute on Minority Health and Health Disparities
(NIMHD)
Phone: 301-594-8704
Email: [email protected]
David F Owens, PhD
National Institute of Neurological Disorders and Stroke
(NINDS)
Phone: 301-496-1447
Email: [email protected]
Karen Huss, PhD, RN
National Institute of Nursing Research (NINR)
Phone: 301-594-5970
Email: [email protected]
Hua-Chuan Sim, MD
National Library of Medicine (NLM)
Phone: 301-594-4882
Email: [email protected]
John D. Harding, PhD
Office of Research Infrastructure Programs (ORIP)
Phone: 301-435-0776
Email: [email protected]
Barbara Sina
Fogarty International Center (FIC)
Phone: 301-402-9467
Email: [email protected]
Weihua Luo, PhD
Center for Scientific Review (CSR)
Telephone: 301-435-1170
Email: [email protected]
Gloria Berrios
National Center for Advancing Translational Sciences (NCATS)
Phone: 301-435-0875
Email: [email protected]
Shelley M. Carow
National Center for Complementary and Alternative Medicine
(NCCAM)
Phone: 301-594-3788
Email: [email protected]
Crystal Wolfrey
National Cancer Institute (NCI)
Phone: 240-276-6277
Email: [email protected]
William W. Darby
National Eye Institute (NEI)
Phone: 301-451-2020
Email: [email protected]
Cheryl Chick
National Human Genome Research Institute (NHGRI)
Phone: 301-435-7858
Email: [email protected]
Jayanthi Regunathan
National Heart, Lung and Blood Institute (NHLBI)
Phone: 301-435-0175
Email: [email protected]
Bryan S. Clark, MBA
National Institute of Child Health and Human Development
(NICHHD)
Phone: 301-435-6975
Email: [email protected]
Earl C. Melvin
National Institute of General Medical Sciences (NIGMS)
Phone: 301-594-3912
Email: [email protected]
Traci Lafferty
National Institute on Aging (NIA)
Phone: 301-496-8987
Email: [email protected]
Judy Fox
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phone: 301-443-4704
Email: [email protected]
Gregory P. Smith
National Institute of Allergy and Infectious Diseases (NIAID)
Phone: 301- 402-5540
Email: [email protected]
Andrew Jones
National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS)
Phone: 301-435-0610
Email: [email protected]
James Huff
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Phone: 301-451-4786
Email: [email protected]
Christopher Myers
National Institute on Deafness and Other Communication
Disorders (NIDCD)
Phone: 301-435-0713
Email: [email protected]
Dede Rutberg
National Institute of Dental and Craniofacial Research (NIDCR)
Phone: 301-594-4798
Email: [email protected]
Bob Pike
National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK)
Phone: 301-594-8854
Email: [email protected]
Dorothy Duke
National Institute of Environmental Health Sciences (NIEHS)
Phone: 919- 541-2749
Email: [email protected]
Rebecca Claycamp, M.S.
National Institute of Mental Health (NIMH)
Phone: 301-443-2811
Email: [email protected]
Priscilla Grant, JD
National Institute on Minority Health and Health Disparities
(NIMHD)
Phone: 301-594-8412
Email: [email protected]
Tijuanna Decoster
National Institute of Neurological Disorders and Stroke
(NINDS)
Phone: 301-496-9231
Email: [email protected]
Ron Wertz
National Institute of Nursing Research (NINR)
Phone: 301-594-2807
Email: [email protected]
Amy Keener
National Library of Medicine (NLM)
Phone: 301-496-6131
Email: [email protected]
Liz Cleveland Whittington
Fogarty International Center (FIC)
Phone: 301-451-6830
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
| ||||||
Department of Health and Human Services (HHS) |
||||||
NIH... Turning Discovery Into Health® |